Ru Wei Wang
Director/Miembro de la Junta en Genor Biopharma Co., Ltd. .
Origen de la red de primer grado Ru Wei Wang.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
Genor Biopharma Co., Ltd.
 Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China.
7
| Holding Company | Biotechnology | 7 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Ru Wei Wang a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Stanford University | College/University | Graduate Degree | |
| Yale University | College/University | Graduate Degree | |
| University of Toronto | College/University | Doctorate Degree | |
| The Hong Kong University of Science & Technology | College/University | Undergraduate Degree | |
Citigroup Global Markets Asia Ltd.
 Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Investment Banks/Brokers | Corporate Officer/Principal | |
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. | Pharmaceuticals: Other | Director/Board Member | |
| WALVAX BIOTECHNOLOGY CO., LTD. | Biotechnology | Chairman Corporate Officer/Principal | |
Shanghai Zerun Biotechnology Co., Ltd.
 Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member | |
Jiangsu Convac Biotechnology Co., Ltd.
 Jiangsu Convac Biotechnology Co., Ltd. BiotechnologyHealth Technology Jiangsu Convac Biotechnology Co., Ltd. engages in the research and development, production, and sale of biological products. It offers new vaccines, genetic modified drugs and in vitro diagnostic reagents. The company was founded on October 13, 2011 and is headquartered in Taizhou, China. | Biotechnology | Director/Board Member | |
| Shanghai Panxin Equity Investment Management Co. Ltd. | Chief Investment Officer | ||
| SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Miscellaneous Commercial Services | Director/Board Member | |
Thousand Oaks Biologics, Inc.
 Thousand Oaks Biologics, Inc. BiotechnologyHealth Technology Thousand Oaks Biologics, Inc. engages in the biopharmaceutical research and development in China, including process detection technology development and validation, process amplification, stability investigation, and pre-clinical to clinical phase sample cGMP standards. The company was founded on March 14, 2017 and is headquartered in Hainan, China. | Biotechnology | Director/Board Member | |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
 PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Miscellaneous Commercial Services | Director/Board Member | |
| GEMPHARMATECH CO., LTD. | Biotechnology | Director/Board Member | |
| ZHAOKE OPHTHALMOLOGY LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| GENOR BIOPHARMA HOLDINGS LIMITED | Biotechnology | President Chief Executive Officer Director/Board Member Director/Board Member | |
| Tayu Huaxia Biotech Medical Group Co Ltd | Chief Executive Officer |
Estadísticas
Internacional
| China | 11 |
| Estados Unidos | 4 |
| Hong-Kong | 4 |
| Canadá | 2 |
| Islas Caimán | 2 |
Sectorial
| Health Technology | 10 |
| Consumer Services | 5 |
| Commercial Services | 3 |
| Finance | 2 |
Operativa
| Director/Board Member | 18 |
| Corporate Officer/Principal | 4 |
| Chief Executive Officer | 4 |
| Chairman | 3 |
| President | 2 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Yu Chen | 11 |
| Feng Guo | 6 |
| Yun Chun Li | 4 |
| Xin Hua Zhou | 4 |
| Ming Li | 2 |
| Yue Zhong Chen | 1 |
| Rui Tang | 1 |
- Bolsa de valores
- Insiders
- Ru Wei Wang
- Conexiones Empresas
